Introduction
============

Prostate cancer is the most commonly diagnosed malignancy and the second leading cause of cancer death among men in the United States. It is estimated that approximately 180,890 new cases of prostate cancer and 26,120 deaths from prostate cancer occurred in the USA in 2016 ([@b1-ijo-51-01-0223]). The common risk factors for prostate cancer are age, race/ethnicity, geography, family history and lifestyle ([@b2-ijo-51-01-0223]). Depending on the severity of the disease, current treatment options for prostate cancer include single or a combination of therapies such as active surveillance, surgery, radiation therapy, chemotherapy, hormone therapy or vaccines ([@b3-ijo-51-01-0223]). Although these interventions have significantly improved the quality of life of the patients and the overall survival rates, effective treatment of prostate cancer is still limited due to the major challenges such as genetic heterogeneity, tumor recurrence (\~30% of the cases) and resistance to conventional chemotherapeutic drugs ([@b4-ijo-51-01-0223]--[@b6-ijo-51-01-0223]). Therefore, it is crucial to develop novel preventive and therapeutic strategies that have the potential to improve outcomes for prostate cancer patients.

Epidemiological studies have shown that there is a significant disparity in incidence and mortality rates of prostate cancer among different countries, with the highest rates in the USA and European countries and the lowest rates in Asian countries such as Japan and China ([@b7-ijo-51-01-0223],[@b8-ijo-51-01-0223]). This wide variability in the prostate cancer rates across countries suggests that several factors including genetic, epigenetic and environmental differences play a key role in the etiology of the disease. Notably, it has been shown that Asian immigrants in the USA have an increased incidence of prostate cancer compared to those individuals with the same genetic background who live in Asia, indicating that environmental factors, especially the diet, are major determinants of prostate cancer incidence ([@b9-ijo-51-01-0223]). One of the remarkable dietary differences between Asian and Western countries is the amount of soy-based food consumption. Asian populations consume high quantities of soy food which is rich in isoflavones (\~2 g of isoflavones per kg of fresh soybean) ([@b10-ijo-51-01-0223]). It has been shown that plasma and prostatic fluid concentrations of isoflavones in Asian men are 10 to 100 times higher than those in Western men, with particularly high levels of the isoflavone genistein ([@b11-ijo-51-01-0223],[@b12-ijo-51-01-0223]). An increasing body of population-based studies has demonstrated that high intake of soy isoflavones are associated with a 25--30% reduced risk of prostate cancer ([@b13-ijo-51-01-0223],[@b14-ijo-51-01-0223]).

As the major biologically active isoflavone in the soy diet, genistein has been extensively investigated for its chemopreventive potential in various types of cancer, including prostate cancer. The average daily intake of genistein in Asian populations has been shown to be 20--80 mg whereas it is 1--3 mg in the USA, supporting the protective effects of genistein against prostate cancer in Asian men ([@b15-ijo-51-01-0223]). Genistein reaches plasma concentrations of 1--5 *µ*M 6--8 h after intake of soy-rich diet ([@b11-ijo-51-01-0223],[@b16-ijo-51-01-0223]). The plasma half-life of genistein has been reported as 7.9 h in adults. In addition, concentrations of total soy isoflavones in prostate tissue have been shown \~6-fold higher than serum levels of isoflavones ([@b17-ijo-51-01-0223]). Safety and pharmacokinetic studies of soy isoflavones have demonstrated that minimal clinical toxicity was observed in healthy subjects administered with purified soy isoflavones at doses that exceed normal dietary intakes ([@b18-ijo-51-01-0223]).

Due to its structural similarity to the steroid hormone 17β-estradiol, genistein binds to estrogen receptors, ER-α and ER-β, with a higher affinity to ER-β, and acts as a natural selective estrogen receptor modulator ([@b16-ijo-51-01-0223],[@b19-ijo-51-01-0223],[@b20-ijo-51-01-0223]). Genistein exerts its inhibitory effects on prostate cancer cells by upregulating the expression of ER-β, which has anti-proliferative and pro-apoptotic roles in prostate cells ([@b21-ijo-51-01-0223],[@b22-ijo-51-01-0223]). In addition to its estrogenic activities, genistein regulates androgen receptor (AR)-mediated pathways in prostate cancer ([@b23-ijo-51-01-0223],[@b24-ijo-51-01-0223]). Of note, it has been shown that the inhibitory effect of genistein on AR expression is also mediated by ER-β ([@b25-ijo-51-01-0223]). Several other molecular mechanisms underlying the preventive effects of genistein on prostate cancer include the inhibition of cell proliferation by inducing G1 and/or G2/M cell cycle arrest ([@b26-ijo-51-01-0223]--[@b28-ijo-51-01-0223]), angiogenesis ([@b29-ijo-51-01-0223],[@b30-ijo-51-01-0223]) and metastasis ([@b31-ijo-51-01-0223]--[@b33-ijo-51-01-0223]) and induction of apoptosis ([@b34-ijo-51-01-0223],[@b35-ijo-51-01-0223]). Genistein exerts its pleiotropic effects in the context of prostate cancer through modulation of several cell signal transduction pathways such as IGF-1 ([@b36-ijo-51-01-0223]), TGF-β ([@b37-ijo-51-01-0223]), Wnt/β-catenin ([@b36-ijo-51-01-0223]), NF-κB ([@b38-ijo-51-01-0223]), AKT and MAPK ([@b39-ijo-51-01-0223]) signaling. This modulation could be by direct binding to nuclear receptors or modification of the phosphorylation state of signal transduction proteins. In addition, genistein inhibits tyrosine kinase activities ([@b40-ijo-51-01-0223]) and shows antioxidant properties ([@b41-ijo-51-01-0223],[@b42-ijo-51-01-0223]) in prostate cells. Swami *et al* ([@b43-ijo-51-01-0223]) demonstrated that genistein reduces prostate cancer progression by inhibiting prostaglandin synthesis and activity. Genistein has also been reported to have possible effects on DNA damage and repair in prostate cancer cells ([@b42-ijo-51-01-0223]). Moreover, genistein inhibits DNA methylation ([@b44-ijo-51-01-0223]--[@b48-ijo-51-01-0223]) and histone modifications ([@b47-ijo-51-01-0223],[@b48-ijo-51-01-0223]) and regulates miRNAs ([@b49-ijo-51-01-0223]--[@b52-ijo-51-01-0223]) in prostate cancer. It is of interest that genistein has been shown to enhance the efficacy of radiotherapy and chemotherapy ([@b53-ijo-51-01-0223],[@b54-ijo-51-01-0223]).

Although numerous *in vitro* and *in vivo* studies have been conducted to understand the protective effects of genistein against prostate cancer demonstrated by epidemiological studies, the molecular mechanisms that govern how genistein affects the pathogenesis of prostate cancer still remain elusive. It is noteworthy that a major challenge is the wide variability of the effects of genistein depending on the dose, the form of administration, or the timing and duration of exposure ([@b55-ijo-51-01-0223]). Despite the wealth of studies performed in human cell lines and animal models, only a few prospective randomized clinical trials have been conducted to examine the molecular effects of genistein on prostate cancer. In the present study, to the best of our knowledge for the first time, we investigated the effects of genistein intervention on global methylation and gene expression patterns in patients with localized prostate cancer, and identified novel targets that are differentially modulated by genistein supplementation, providing further mechanistic insights into the effects of genistein on prostate carcinogenesis.

Materials and methods
=====================

Subjects
--------

Prostate specimens from a clinical trial of genistein supplementation prior to prostatectomy ([@b56-ijo-51-01-0223]) were analyzed for global changes in DNA methylation and gene expression. Participants were recruited from the outpatient clinic at the Department of Urology, Oslo University Hospital, Oslo, Norway between April 2007 and August 2008. The study was approved by the Norwegian Medicines Agency, the Regional Ethics Committee, the Privacy Ombudsman and the Prostate Biobank at the Oslo University Hospital, Aker.

Genome-wide methylation profiling
---------------------------------

Total DNA was isolated from frozen prostate tissues using DNeasy Blood and Tissue kit (Qiagen, Valencia, CA, USA) according to the manufacturer\'s instructions. DNA was submitted to the Emory Integrated Genomics Core for DNA methylation analysis using Illumina HumanMethylation450 BeadChip Microarrays. Methylation data are available on GEO (accession number GSE84749).

Genome-wide expression profiling
--------------------------------

Total RNA was extracted from frozen prostate tissues using the mirVana miRNA Isolation kit (Life Technologies, Grand Island, NY, USA), followed by RNA clean-up using the RNeasy Mini kit (Qiagen). Total RNA was submitted to the Emory Integrated Genomics Core for gene expression analysis using the Illumina HumanHT-12 v4 Expression BeadChip Microarray. Microarray data are available on GEO (accession number GSE84748).

Quantitative PCR (qPCR) analysis
--------------------------------

RNA was reverse-transcribed into cDNA using iScript cDNA Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). Primers were designed using Primer3 tool. Sequences of the primers are listed in [Table I](#tI-ijo-51-01-0223){ref-type="table"}. qPCR was performed using iQ SYBR-Green Supermix (Bio-Rad Laboratories) on a Bio-Rad iCycler according to the manufacturer\'s protocols. Human β-actin gene, which has been shown to be a valid reference gene for normalization of qPCR in human tissue samples of prostate cancer, was used as an internal control in the present study ([@b57-ijo-51-01-0223]). Normal prostate tissue sample was used as the calibrator. The relative changes in gene expression data were analyzed by the 2^−ΔΔCT^ method. Triplicates were run for each sample. Data are presented as the mean ± standard deviation.

Data analysis
-------------

Gene expression analysis was performed using GenePattern ComparativeMarkerSelection module ([@b58-ijo-51-01-0223]) comparing genistein-treated tumors to placebo-treated tumors. Illumina Microarray data were filtered to include genes that were detected (P\<0.05) in at least one experimental group to result in a dataset of 15918 genes for analysis. The comparative marker selection module of GenePattern was used to compute two-sided Student\'s t-tests between groups with 10,000 permutations to compute false discovery rates. The random seed used was 779948241. Hierarchical clustering was performed using Cluster software ([@b59-ijo-51-01-0223]) and Java TreeView ([@b60-ijo-51-01-0223]). Methylation microarray analysis was performed in R using CpGassoc module in Bioconductor ([@b61-ijo-51-01-0223]). Data from the 450K probes was filtered to those in which the maximum - minimum β-value was \>0.2 to result in 160K probes for differential methylation analysis. CpGassoc was used to identify 162 significant probes that were differentially methylated. Three probes were differentially methylated between genistein-treated tumor samples and placebo-treated tumor samples, three probes were significant between genistein-treated tumor samples and normal samples and 156 were significantly different between placebo-treated tumor samples and normal samples.

Statistical analysis
--------------------

Mann-Whitney U test (two-tailed) was used to determine significant differences between two groups of data. P\<0.05 was considered as statistically significant.

Results
=======

Clinicopathological characteristics
-----------------------------------

We analyzed prostate tissue samples from a previous study, which was a randomized, placebo-controlled, double-blind Phase 2 clinical trial on Norwegian patients with localized prostate cancer who received 30 mg synthetic genistein or placebo capsules daily for 3--6 weeks before radical prostatectomy ([@b56-ijo-51-01-0223]). The clinical and pathological characteristics of the cases were previously described ([@b56-ijo-51-01-0223]). The availability of frozen tissue limited the sample size in this study and we investigated the DNA methylation and gene expression levels of prostate tumor samples from 10 patients who received genistein and 10 patients who received placebo. Four adjacent normal prostate tissue samples were also analyzed. Clinical data for the 20 patients analyzed here are provided in [Table II](#tII-ijo-51-01-0223){ref-type="table"}. There were no statistically significant differences in age, levels of serum PSA and Gleason score between the two treatment groups.

Differential methylation in genistein-treated tissue compared with placebo-treated tissue
-----------------------------------------------------------------------------------------

The genome-wide DNA methylation profiles of a total of 24 prostate samples from tumor or normal tissues were generated using Illumina HumanMethylation450 BeadChip kit. Methylation status of each sample was analyzed for 485,577 sites, covering 21,231 genes. We compared the methylation profiles of genistein-treated tumor samples with placebo-treated cases. In general, methylation changes were modest, and there was no significantly differentially methylated gene after correction for multiple hypothesis testing. However, uncorrected P-values indicated that *RBM28* and *CYTSB* genes were demethylated in genistein-treated tumor samples compared to placebo-treated samples. The lack of statistical significance was likely due to the small numbers of samples analyzed in this study. We did observe 156 probes with significantly increased methylation in placebo-treated tumor tissues vs. normal tissues that were not significant between genistein-treated tumor tissues and normal tissues, suggesting that genistein may have had some demethylation effects (available upon request). These 156 probes corresponded to at least 92 separate genes including *ADCY4*, *ALOX12*, *HAAO*, *LRRC4*, *NEU1*, *RAPGEFL1* and *WNT7B* ([Table III](#tIII-ijo-51-01-0223){ref-type="table"}).

Gene expression profiling changes after genistein treatment
-----------------------------------------------------------

To identify molecular effects of genistein on mRNA levels in prostate cancer, we compared gene expression profiles of genistein-treated tumors with placebo-treated samples. Once again, there were no differentially expressed probes that remained statistically significant after correction for multiple hypothesis testing. However, there were 628 probes that reached nominally significant P-values (available upon request). Hierarchial clustering of this dataset showed strong segregation of patients with and without genistein treatment ([Fig. 1](#f1-ijo-51-01-0223){ref-type="fig"}). The genes with nominally significant P-values included *NOTCH3*, *JAG1*, *CKS2*, *HIF1A*, *CDK6*, *MYC*, *CD24*, *AMACR*, *MMP26* and *SPP1* genes ([Table IV](#tIV-ijo-51-01-0223){ref-type="table"}). *NEU1* and *ADCY4* did not reach nominal significance but had a trend towards significance, and integration of the methylation data with the paired gene expression profiling data indicated decreased methylation status and increased expression levels of *ADCY4* and *NEU1* genes in genistein-treated cases.

Validation of microarray data
-----------------------------

We investigated the expression levels of 12 selected genes ([Table IV](#tIV-ijo-51-01-0223){ref-type="table"}) in all 24 samples analyzed by microarrays using qPCR, and observed that microarray data were correlated with qPCR results ([Fig. 2](#f2-ijo-51-01-0223){ref-type="fig"}). The increase in the qPCR expression levels of *NOTCH3* and *JAG1* genes in genistein-treated tumors compared to placebo-treated tumors were statistically significant by Mann-Whitney U test.

Enrichment analysis
-------------------

We performed gene enrichment analysis on the 628 nominally significant probes that were differentially expressed between genistein and placebo samples ([Table V](#tV-ijo-51-01-0223){ref-type="table"}) using Ingenuity Pathway Analysis ([@b62-ijo-51-01-0223]) and the DAVID Knowledgebase ([@b63-ijo-51-01-0223]). P-value indicates hypergeometric distribution P-values of overlap for gene sets and functional categories. FDR indicates false discovery rate corrected P-values of overlap. Activation z-score is an indication of the consistency of up and downregulated members of a gene set such as a biological function (top table) or targets of an upstream regulator (middle table). Activation z-scores \>2 or \<−2 are statistically significant for consistency of activation or inhibition. Molecules indicate the number of molecules in the set of 628 analyzed probes that overlap with a given category. Mechanistic network indicates the total number of target genes of an upstream regulator, and the number of overlapping genes is indicated in parentheses. We observed enrichment for terms associated with angiogenesis, apoptosis, epithelial to mesenchymal transition, tumor progression and PDGF binding. Analysis of potential upstream regulators by IPA analysis suggested that PTEN and PDGF were activated, while MYC, β-estradiol, glucocorticoid receptor NR3C1 and interferon-γ were repressed in response to genistein treatment.

Discussion
==========

To the best of our knowledge, the present study is the first highlighting the effects of genistein on global changes in DNA methylation and gene expression in patients from a clinical trial of genistein in prostate cancer. Integrative analysis of whole genome methylation and expression profiling identified a number of candidate differentially methylated sites and expressed sites between placebo and genistein groups. However, the differences between placebo and genistein groups were not statistically significant after correction for multiple hypothesis testing, possibly due to the small number of the cases in this study. Although the genistein-induced alterations are not significant, these results may help to elucidate the molecular mechanisms underlying the activities of genistein in prostate cancer. Genome-wide DNA methylation arrays showed that a number of genes, including *RBM28* and *CYTSB*, appeared to be demethylated in the genistein-treated tumor samples compared to the samples in the placebo group. However, we did not observe any alterations in the expression levels of these genes. Among the differentially expressed genes identified by microarray analysis were *CKS2*, *NOTCH3*, *HIF1A*, *CDK6*, *JAG1*, *NEU1*, *ADCY4*, *MYC*, *CD24*, *AMACR*, *MMP26* and *SPP1*. Microarray data were confirmed by qPCR analysis of these genes. Other genes with nominal significance by microarray but not tested by qPCR included *ZNF639*, *CRIM1*, *PGC* and *USP54* (available upon request).

It is of interest to note that DNA methylation status was inversely correlated with gene expression for the *NEU1* and *ADCY4* genes, which had decreased methylation, and increased mRNA expression in the genistein group in comparison with placebo group. Our finding showing the potential of genistein for DNA demethylation is consistent with the previously reported data that suggest genistein acts as a DNMT inhibitor, thereby causing the demethylation of CpG islands in the promoters of genes. For example, genistein has been shown to reactivate the hypermethylated-silenced tumor suppressor genes, including *p16INK4a*, retinoic acid receptor β (*RARβ*) and *O*6-methylguanine methyltransferase (*MGMT*), in prostate and esophageal cancer cells ([@b46-ijo-51-01-0223]). Moreover, genistein has been implicated in demethylation of *WNT5a* promoter in colon cancer cells ([@b64-ijo-51-01-0223]). One of the genes shown to be demethylated by genistein in the present study is ADCY4, which is a member of the family of adenylate cyclases, the membrane-bound enzymes that catalyze formation of the secondary messenger cyclic adenosine monophosphate (cAMP) ([@b65-ijo-51-01-0223]). Consistent with our finding, it has been recently shown that ADCY4 is a DNA methylation marker representing early epigenetic events in prostate tumorigenesis, supporting our hypothesis that genistein may reverse the pattern of DNA methylation in ADCY4 in prostate cancer ([@b66-ijo-51-01-0223]). The other gene that was modulated by genistein intervention in the present study was NEU1, which is a lysosomal sialidase involved in glycoconjugate catabolism and cellular signaling, including immune responses and elastin receptor-mediated signal transduction ([@b67-ijo-51-01-0223]). In fact, NEU1 is critical for desialylation of integrin β4 and inhibition of FAK, leading to suppression of liver metastases in colon cancer ([@b68-ijo-51-01-0223]). Kato *et al* ([@b69-ijo-51-01-0223]) has reported that NEU1 overexpression resulted in suppression of lung metastasis in melanoma. In addition, suppression of *NEU1* by *miR-125b* has been shown to promote migration, invasion and metastasis in gastric cancers ([@b70-ijo-51-01-0223]). However, NEU1 can also have pro-metastatic effects in pancreatic and ovarian cancers ([@b71-ijo-51-01-0223]), and thus it is not entirely clear what the overall impact of increased NEU1 levels might be in prostate cancer. Therefore, it is important to examine the NEU1 expression changes at the protein level, and molecular and cellular studies are required to assess the functional consequences of changes induced by NEU1 upregulation in prostate cancer cells.

Among the differentially expressed genes that were validated by qPCR, only the expression of *NOTCH3* and *JAG1* mRNAs were significantly higher in the genistein group compared to the placebo group by qPCR. Based on our findings at mRNA level without any confirmation at the protein or functional level, it would be speculative to suggest that Notch signaling may play a role in the mechanism of action of genistein on prostate cancer. NOTCH3 is important for TGFβ-induced EMT in prostate cancer ([@b72-ijo-51-01-0223]), and is induced by hypoxia and contributes to prostate cancer progression ([@b73-ijo-51-01-0223]). The Notch ligand JAG1 is also associated with more aggressive prostate cancer ([@b74-ijo-51-01-0223],[@b75-ijo-51-01-0223]), EMT and angiogenesis ([@b76-ijo-51-01-0223]). However, a tumor suppressive role of Notch signaling has also been reported in hypoxia-induced neuroendocrine differentiation of prostate cancer cells as well as in other cancer types including bladder cancer, hematological malignancies, glioma, thyroid carcinoma and lung cancer ([@b77-ijo-51-01-0223]--[@b82-ijo-51-01-0223]), indicating the possibility that increased *NOTCH3/JAG1* expression by genistein treatment may improve outcomes through its tumor suppressor function. Our data suggest that further studies to delineate the effect of genistein on the Notch signaling pathway in prostate cancer may be warranted.

Enrichment analyses of mRNA changes induced by genistein indicated that subtle changes in gene expression observed between genistein and placebo samples are consistent with many previously reported effects of genistein on critical tumor pathways including PTEN, PDGF, MYC, β-estradiol, glucocorticoid receptor and interferon-γ ([@b41-ijo-51-01-0223],[@b83-ijo-51-01-0223]--[@b89-ijo-51-01-0223]). Genistein appeared to promote PTEN activity and inhibit MYC activity, consistent with its potential utility in improving outcomes in prostate cancer.

In summary, our results indicate that genistein intervention induces modulation of several genes, including *NOTCH3*, *JAG1*, *ADCY4* and *NEU1*, suggesting that these genes may have the potential to be novel molecular targets of genistein in prostate cancer. These genes are involved in many critical biological processes including cell cycle, angiogenesis, cellular immune response and intracellular signal transduction, providing additional insight into the multiple molecular pathways involved in prostate tumorigenesis. However, further mechanistic studies are required to investigate the effects of genistein on the regulation of the expression of these genes at the protein level and cellular functions. These findings may then contribute towards designing novel strategies for prevention and treatment of prostate cancer. One caveat of gene expression profiling studies is the incapability of identification of mechanisms of action that are modulated at post-transcriptional level, suggesting the possibility that genistein may alter additional cellular processes. Another point that needs to be made is timing and duration of exposure to genistein. Case control studies have demonstrated that high consumption of soy early in life (during childhood and/or adolescence) is associated with 25--60% reductions in breast cancer risk ([@b90-ijo-51-01-0223],[@b91-ijo-51-01-0223]). Similarly, high soy intake at puberty, the period during which prostate undergoes androgen-induced growth, might be more effective in prevention of prostate cancer. A limitation of the present study is the small number of patient samples. Further large randomized controlled clinical trials would provide more definitive results of the effects of genistein on patient prostate tissues.
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###### 

Sequences of the primers used in the quantitative PCR analysis.

  Primer name   Primer sequence (5′→3′)
  ------------- --------------------------
  CKS2-FP       TTAGTCTCCGGCGAGTTGTTG
  CKS2-RP       CATAACATGCCGGTACTCGT
  JAG1-FP       AGTCGTGCATGCTCCAATCG
  JAG1-RP       CCCCACACACCTTGGCTC
  NOTCH3-FP     GATGTGGACGAGTGTGCTGG
  NOTCH3-RP     CAGGCATGGGTTGGGGTC
  MMP26-FP      GGACTTTGTTGAGGGCTATTTCCA
  MMP26-RP      GGAGGTGTCGGACCCATCAG
  HIF1A-FP      CACCACAGGACAGTACAGGAT
  HIF1A-RP      CGTGCTGAATAATACCACTCACA
  CDK6-FP       GCTGACCAGCAGTACGAATG
  CDK6-RP       GCACACATCAAACAACCTGACC
  CD24-FP       CGCGGACTTTTCTTTTGGGG
  CD24-RP       ACTGGAATAAATCTGCGTGGGT
  AMACR-FP      CCGTTCTGTGCTATGGTCCTG
  AMACR-RP      AGCCTTGGATTTTCCCGCTG
  MYC-FP        CCTACCCTCTCAACGACAGC
  MYC-RP        TTGTTCCTCCTCAGAGTCGC
  SPP1-FP       CAAACGCCGACCAAGGAAAA
  SPP1-RP       GGCCACAGCATCTGGGTATT
  NEU1-FP       CGCAGCTATGATGCCTGTGA
  NEU1-RP       GGTCAGGTTCACTCGGAACTC
  ADCY4-FP      CCTGGGACCAGGTGTCCTAT
  ADCY4-RP      CAAGATACAGCCCGAGGACC
  β-actin-FP    CACAGAGCCTCGCCTTTGCC
  β-actin-RP    TGACCCATGCCCACCATCAC

qPCR analysis.

###### 

Clinical data for the 20 patients analyzed in the present study.

  Treatment          Patient ID   Gleason   Gleason Sum   Stage   Age          PSA
  ------------------ ------------ --------- ------------- ------- ------------ -----------
  Genistein (n=10)   1            3+4       7             2       68           12.0
  7                  3+4          7         2             68      10.9         
  8                  3+3          6         2             59      6.2          
  10                 3+4          7         3a            61      5.1          
  13                 3+3          6         2             58      7.6          
  14                 4+3          7         3a            64      8.5          
  17                 4+4          8         2             61      6.1          
  18                 3+3          6         2             57      6.0          
  19                 3+3          6         2             63      7.8          
  20                 3+4          7         2             68      7.9          
  Average (SD)                              6.7 (0.7)             62.7 (4.2)   7.8 (2.2)
  Placebo (n=10)     24           3+3       6             2       61           6.4
  25                 3+3          6         2             57      4.2          
  26                 3+4          7         3a            68      9.9          
  27                 4+4          8         2             69      9.2          
  30                 4+3          7         2             55      5.1          
  33                 3+3          6         2             56      6.4          
  34                 3+3          6         2             63      7.6          
  35                 3+4          7         3a            60      5.7          
  38                 3+4          7         2             62      9.9          
  39                 3+3          6         2             66      7.0          
  Average (SD)                              6.6 (0.7)             61.7 (4.9)   7.1 (2.0)

###### 

List of 156 differentially methylated probes (92 genes).

  Target ID     Gene name                   P-value (GT vs. PT)   P-value (GT vs. N)   P-value (PT vs. N)
  ------------- --------------------------- --------------------- -------------------- --------------------
  cg00353923    LRRC4; SND1                 ns                    ns                   0.000214451
  cg00420348    EFCAB4A                     ns                    ns                   0.000247793
  cg00459232    CD9                         ns                    ns                   0.000270319
  cg00494665                                ns                    ns                   0.000274219
  cg00506168    PDXK                        ns                    ns                   0.000515556
  cg00578638    RAPGEFL1                    ns                    ns                   3.67E-05
  cg01224366    PDXK                        ns                    ns                   0.000393857
  cg01228355    CORIN                       ns                    ns                   0.000881032
  cg01233722    NFATC4                      ns                    ns                   1.51E-05
  cg01398859                                ns                    ns                   0.000942104
  cg01561916    HAAO                        ns                    ns                   0.00015216
  cg01684881    FZD2                        ns                    ns                   0.000472597
  cg01856645    DMGDH; BHMT2                ns                    ns                   0.000876054
  cg02072400                                ns                    ns                   3.73E-05
  cg02131967    ACE                         ns                    ns                   0.000468338
  cg02215070    AKR1B1                      ns                    ns                   0.000607743
  cg02493798    ALOX12                      ns                    ns                   0.000106934
  cg02534363    NBEAL2                      ns                    ns                   0.000263128
  cg02659920    EPS8L2                      ns                    ns                   0.000563556
  cg02665650    ANKS1A                      ns                    ns                   0.000420543
  cg02683114    C2orf84                     ns                    ns                   3.28E-05
  cg02915422                                ns                    ns                   0.000993538
  cg03119308    RBM28                       0.000122845           ns                   ns
  cg03404566    ALOX12                      ns                    ns                   9.44E-05
  cg03407747    ALOX12                      ns                    ns                   0.000320776
  cg03452174    RAB34                       ns                    ns                   0.000820466
  cg03456213    C9orf3                      ns                    ns                   0.000620827
  cg03760483    ALOX12                      ns                    ns                   0.000249903
  cg03762994    ALOX12                      ns                    ns                   0.000338148
  cg03782157                                ns                    ns                   0.000566959
  cg03787864    CYBA                        ns                    ns                   0.000360395
  cg03955537    TBCD                        ns                    ns                   0.000449056
  cg03957885                                ns                    ns                   0.000500821
  cg04034767    GRASP                       ns                    ns                   0.000526517
  cg04178858    RAPGEFL1                    ns                    ns                   0.000378136
  cg04194674    SRCIN1                      ns                    ns                   0.000665658
  cg04332818    FGF2                        ns                    ns                   0.000648814
  cg04555220    SEMA5A                      ns                    ns                   0.000994353
  cg04621728                                ns                    ns                   0.000680098
  cg04797170                                ns                    ns                   0.000729496
  cg05209996                                ns                    ns                   0.000724896
  cg05897210    DTHD1                       ns                    ns                   0.000252462
  cg05950572    SPON1                       ns                    ns                   0.000546993
  cg06085985    EFCAB4A                     ns                    ns                   0.000230613
  cg06590173    TPM4                        ns                    ns                   0.000778707
  cg06607764    CYTH1                       ns                    ns                   0.000254746
  cg06749789    THAP4                       ns                    ns                   0.000864909
  cg06763054    MTMR7                       ns                    ns                   0.000353509
  cg06795971    TET2                        ns                    ns                   0.000140266
  cg06835156    C14orf70                    ns                    0.000524942          ns
  cg06945399    LRRC4; SND1                 ns                    ns                   7.67E-05
  cg07016556    BAHCC1                      ns                    ns                   0.000590044
  cg07235805    PARD6G                      ns                    ns                   0.000661791
  cg07251099    CD200                       ns                    ns                   0.000689192
  cg07522516    ZAR1                        ns                    ns                   0.000692555
  cg07834955    SFRP5                       ns                    ns                   0.000372927
  cg07871590    LRRC4;SND1                  ns                    ns                   0.000127567
  cg07924363    MGC16121; MIR424; MIR503    ns                    0.000320255          ns
  cg08194377    ANKS1A                      ns                    ns                   0.000793165
  cg08248285    CFL2                        ns                    ns                   0.000346449
  cg08298946                                ns                    ns                   0.000455024
  cg08330950                                ns                    ns                   0.000195062
  cg08421126    HAAO                        ns                    ns                   0.000388422
  cg08572315                                ns                    ns                   0.000667361
  cg08617833    SMARCA1                     ns                    ns                   0.000373883
  cg09088834    NINL                        ns                    ns                   0.000442225
  cg09246479    C22orf45; UPB1              ns                    ns                   0.00010158
  cg09456782    TMCO3; DCUN1D2              ns                    ns                   0.000792785
  cg09480054    HAAO                        ns                    ns                   0.000295903
  cg09580336    ATP1A1                      ns                    ns                   0.000440859
  cg09581551    SOBP                        ns                    ns                   0.000280079
  cg09667289    FMN1                        ns                    ns                   0.000712725
  cg09737314    ALOX12                      ns                    ns                   0.000673337
  cg09920557    ACE                         ns                    ns                   0.000673976
  cg09963123    FLJ13197; KLF3              ns                    ns                   0.000654359
  cg10445911                                ns                    ns                   0.00061326
  cg11417025    SOSTDC1                     ns                    ns                   0.000375888
  cg11832404                                ns                    ns                   0.000826709
  cg11942956    EYA4                        ns                    ns                   0.00073108
  cg12177793    NFATC4                      ns                    ns                   0.000965995
  cg12262378    ALOX12                      ns                    ns                   0.000115607
  cg12451530    LOC100302652; GPR75         ns                    ns                   0.000188564
  cg12828075    INSC                        ns                    ns                   0.000784835
  cg13616314    HS3ST3A1                    ns                    ns                   2.38E-05
  cg13801416    AKR1B1                      ns                    ns                   0.000474669
  cg13857811    SLC7A3                      ns                    ns                   0.000228168
  cg14032732    ECHDC3                      ns                    ns                   0.000256212
  cg14243778    CNTN1                       ns                    ns                   0.00077315
  cg14254720    LRRC8C                      ns                    ns                   0.000920384
  cg14287235    ADCY4                       ns                    ns                   0.000228476
  cg14482902    SRCIN1                      ns                    ns                   0.000344968
  cg14500300                                ns                    ns                   8.80E-05
  cg14603620    RAPGEFL1                    ns                    ns                   7.94E-05
  cg14663984    AGRN                        ns                    ns                   0.000843468
  cg14792081                                ns                    ns                   0.000344126
  cg15115171                                ns                    ns                   0.000503109
  cg15673034    DLGAP1                      ns                    ns                   0.000846318
  cg15826437    RAPGEFL1                    ns                    ns                   0.00029995
  cg15998779                                ns                    ns                   0.000211956
  cg16450577    TBCD                        ns                    ns                   0.000368573
  cg16859884                                ns                    ns                   0.000247308
  cg16968985    SEZ6                        ns                    ns                   0.000382576
  cg17011709    CYP26C1                     ns                    ns                   0.000901702
  cg17131553    TRPS1                       ns                    ns                   0.000583708
  cg17165580    CRABP2                      ns                    ns                   0.000197886
  cg17479501    TBCD                        ns                    ns                   0.000197189
  cg17496661                                ns                    0.000436474          0.000459741
  cg17624073    BAHCC1                      ns                    ns                   0.000526316
  cg17729667    NINL                        ns                    ns                   0.000569462
  cg18344652    CNN3                        ns                    ns                   0.000452391
  cg19372602                                ns                    ns                   0.000864447
  cg19467964    TBCD                        ns                    ns                   0.000196505
  cg19499884    LZTS2                       ns                    ns                   0.000537829
  cg19929126    TRIL                        ns                    ns                   0.000632594
  cg20132775    TRPC1                       ns                    ns                   0.000197515
  cg20145692    COL9A2                      ns                    ns                   0.000190537
  cg20276377    C3orf26; FILIP1L; MIR548G   ns                    ns                   6.22E-05
  cg20383155    NEU1; SLC44A4               ns                    ns                   0.000632549
  cg20801007    EFCAB4A                     ns                    ns                   0.000259905
  cg20987431    ZHX1                        ns                    ns                   0.00053928
  cg21079003    RGMA                        ns                    ns                   0.000411886
  cg21116447    NEU1; SLC44A4               ns                    ns                   0.000990119
  cg21543859    RUNX2                       ns                    ns                   0.000760409
  cg21849932    LIME1                       ns                    ns                   0.000537283
  cg21944491    LTBP4                       ns                    ns                   0.000572287
  cg22074576    OSBPL5                      ns                    ns                   0.00073274
  cg22092811    C3orf26; FILIP1L; MIR548G   ns                    ns                   4.30E-05
  cg22413388    WNT7B                       ns                    ns                   0.000992683
  cg22534145    SSTR4                       ns                    ns                   0.000156886
  cg22675801    TRIL                        ns                    ns                   0.000451146
  cg22753340    NEU1; SLC44A4               ns                    ns                   0.000874186
  cg22773555    EFCAB4A                     ns                    ns                   0.00025263
  cg22773661    ZAR1                        ns                    ns                   0.00033279
  cg22871668    EYA4                        ns                    ns                   0.000392704
  cg22878441                                ns                    ns                   0.000393322
  cg23083315    FJX1                        ns                    ns                   0.000288759
  cg23142799    SHISA2                      ns                    ns                   0.000157373
  cg23396786    SFXN5                       ns                    ns                   0.000434986
  cg23425970    HS6ST1                      ns                    ns                   0.00016049
  cg23563927    C10orf93                    ns                    ns                   0.000585909
  cg23684878                                ns                    ns                   0.000735566
  cg23926436                                ns                    ns                   0.00082097
  cg24251193    CRABP2                      ns                    ns                   0.000141885
  cg24331301    CDH23                       ns                    ns                   0.000549748
  cg24878115    SSBP4                       ns                    ns                   0.000354342
  cg24902339    CASC2                       ns                    ns                   0.000256574
  cg25027125    CFL2                        ns                    ns                   0.000978881
  cg25117523    CYTH1                       ns                    ns                   0.000297582
  cg25387565    NEU1                        ns                    ns                   0.000708206
  cg25563256    FGF11                       ns                    ns                   0.000933724
  cg25813864    RAPGEFL1                    ns                    ns                   0.000174816
  cg25834415    IF1A                        ns                    ns                   0.000894051
  Kcg26009486   NFATC4                      ns                    ns                   0.000293111
  cg26360792    HAAO                        ns                    ns                   0.000297095
  cg26558799    TBCD                        ns                    ns                   0.000570916
  cg26607748    TPM2                        ns                    ns                   0.000773141
  cg26846076    CYTSB                       0.000457469           ns                   ns
  cg27191312                                ns                    ns                   0.00012339
  cg27299406    HAAO                        ns                    ns                   0.000380895
  cg27347290    NEU1; SLC44A4               ns                    ns                   0.000429935
  cg27573591    SND1; LRRC4                 ns                    ns                   0.000183694
  rs10033147                                0.00000393            ns                   ns

GT, genistein-treated tumor; PT, placebo-treated tumor; N, normal; NS, not significant.

###### 

Genes with differential gene expression analyzed by qPCR.

  Gene symbol                                              Gene expression fold-change   
  -------------------------------------------------------- ----------------------------- -------
  *CKS2*                                                   −2.02                         −2.50
  *NOTCH3*                                                 1.72                          2.08
  *HIF1A*                                                  −1.63                         −1.80
  *CDK6*                                                   −2.87                         −1.57
  *JAG1*                                                   1.91                          6.00
  *NEU1*[a](#tfn3a-ijo-51-01-0223){ref-type="table-fn"}    1.77                          1.50
  *ADCY4*[a](#tfn3a-ijo-51-01-0223){ref-type="table-fn"}   1.67                          1.60
  *MYC*                                                    −1.57                         −2.30
  *CD24*                                                   −2.02                         −2.64
  *AMACR*                                                  −1.95                         −2.14
  *MMPP26*                                                 −2.78                         −2.84
  *SPP1*                                                   −2.36                         −3.09

Fold changes are genistein-tumor/placebo-tumor

DNA methylation status is correlated with gene expression in *NEU1* and *ADCY4.* qPCR, quantitative PCR.

###### 

Enrichment analysis of 628 nominally significant probes differentially expressed between genistein and placebo groups.

  Analysis   P-value              Activation z-score   No. of molecules      Function
  ---------- -------------------- -------------------- --------------------- ------------------------------------------------------------
  IPA        5.92E-08             0.773                18                    Progression of tumor
  IPA        4.88E-07             1.01                 355                   Abdominal neoplasm
  IPA        1.09E-06             1.927                28                    Differentiation of tumor cell lines
  IPA        1.34E-06             −1.017               19                    Epithelial-mesenchymal transition
  IPA        7.46E-06             2.412                22                    Neuroendocrine tumor
  IPA        7.98E-05             2.054                28                    Necrosis of tumor
                                                                             
  Analysis   P-value of overlap   Activation z-score   Mechanistic network   Upstream regulator
                                                                             
  IPA        3.85E-08             −0.692               184 (16)              NR3C1
  IPA        1.21E-07             1.681                112 (9)               PDGFB
  IPA        2.71E-07             −1.385               167 (15)              β-estradiol
  IPA        2.15E-06             −0.832               144 (13)              IFNG
  IPA        2.17E-06             1.608                141 (16)              PTEN
  IPA        4.59E-06             −2.995               133 (13)              MYC
                                                                             
  Analysis   FDR                  Activation z-score   No. of molecules      Term
                                                                             
  DAVID      7.90E-04             NA                   17                    GO:0005840 ribosome
  DAVID      1.19E-02             NA                   34                    mitochondrion
  DAVID      2.00E-02             NA                   16                    GO:0001568 blood vessel development
  DAVID      1.77E-02             NA                   10                    GO:0019838 growth factor binding
  DAVID      3.52E-02             NA                   7                     GO:0008629 induction of apoptosis by intracellular signals
  DAVID      3.16E-02             NA                   4                     GO:0048407 platelet-derived growth factor binding

[^1]: *Present address:*Department of Environmental and Occupational Medicine, Oslo University Hospital, Oslo, Norway
